Analysis on individual difference in pharmacokinetics of aprepitant and its metabolites, and investigation on predictive parameters of aprepitant response and adverse effects in Japanese patiens
Not Applicable
Recruiting
- Conditions
- head and neck cancer
- Registration Number
- JPRN-UMIN000041069
- Lead Sponsor
- Department of Hospital pharmacy Amaterasu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients discontinuing aprepitant 2. Patients who are judged by physicians as inappropriate for study enrollment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentrations of aprepitant and its metabolites at 24 hours after the last oral administration of aprepitant.
- Secondary Outcome Measures
Name Time Method